Skip to main content
SpringerLink
Log in

Clinical and biological aspects of sentinel node biopsy in malignant melanoma — an update

  • Review
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The diagnostic usefulness of sentinel lymph node biopsy (SLNB) has been well established, but its therapeutic value remains unproven. First introduced by Morton and colleagues, the SLNB procedure is now widely available, and markedly enhances our ability to pathologically stage the regional nodes.

Although the SLN status is acknowledged as the most powerful indicator of prognosis in melanoma, there is no evidence to-date, of survival advantage for complete lymphadenectomy in SLN-positive patients. Also, there is no effective adjuvant therapy that could benefit these sentinel node-positive patients, as yet. Additionally, new data have emerged indicating a possible increase in local/in-transit recurrence following complete lymphadenectomy in sentinel node-positive patients. To understand fully and to evaluate these observations we need information from randomized controlled trials.

Major changes have occurred following the latest revision of melanoma staging system (AJCC, 6th edition). Concerning N category, these include the incorporation of the number of metastatic lymph nodes, the tumour burden of nodal metastases, and the ulceration of the primary tumour. The data obtained from the new staging system will reflect differences in prognosis that were not previously emphasized and which, we hope, will serve as a guide to more accurate analysis of metastatic pathways in cutaneous melanoma as well as a rationale for new forms of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer. 1978;41:948–56.

    Article  PubMed  CAS  Google Scholar 

  2. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the olderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62–70.

    Article  PubMed  CAS  Google Scholar 

  3. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg. 1991;214:627–36.

    Article  PubMed  CAS  Google Scholar 

  4. Balch CM, Soong SJ, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, et al, editors. Cutaneous Melanoma. 2nd ed. Philadelphia, PA: Lippincott; 1992. p. 165–87.

    Google Scholar 

  5. Morton DL, Wanek L, Nizze JA, et al. Improved longterm survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from John Wayne Cancer Clinic. Ann Surg. 1991;214:491–9.

    Article  PubMed  CAS  Google Scholar 

  6. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992;127:392–9.

    PubMed  CAS  Google Scholar 

  7. Reintgen D, Cruse CW, Wells, K, et al. The orderly progression of melanoma nodel metastases. Ann Surg. 1994;220:759–67.

    Article  PubMed  CAS  Google Scholar 

  8. Urist MM, Maddox WA, Kennedy JE, et al. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer. 1983;51:2152–6.

    Article  PubMed  CAS  Google Scholar 

  9. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 1995;5:255–60.

    Article  PubMed  CAS  Google Scholar 

  10. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma-A multicenter trial. Ann Surg. 1999;4:453–65.

    Article  Google Scholar 

  11. Essner R, Bostick PJ, Glass EC, et al. Standardized probe-directed sentinel node dissection in melanoma. Surgery. 2000;127:26–31.

    Article  PubMed  CAS  Google Scholar 

  12. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging. J Clin Oncol. 2001;19:3622–34.

    PubMed  CAS  Google Scholar 

  13. Dessureault S, Soong SJ, Ross MI, et al. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001;8:766–70.

    Article  PubMed  CAS  Google Scholar 

  14. Balch CM, Soong SJ, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 cm to 4 cm). Intergroup Melanoma Surgical trial. Ann Surg Oncol. 2000;7:87–97.

    Article  PubMed  CAS  Google Scholar 

  15. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–66.

    Article  PubMed  CAS  Google Scholar 

  16. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–401.

    Article  PubMed  CAS  Google Scholar 

  17. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 1997;349: 1864–7.

    Article  PubMed  CAS  Google Scholar 

  18. Canavese G, Gipponi M, Catturich, et al. Sentinel lymph node mapping opens a new perspective in the surgical management of early-stage breast cancer: a combined approach with vital blue dye lymphatic mapping and radioguided surgery. Semin Surg Oncol. 1998;15:272–7.

    Article  PubMed  CAS  Google Scholar 

  19. Cody HS, Borgen PI. State-of-the-art approaches to sentinel node biopsy for breast cancer: Study design, patient selection, technique, and quality control at Memo-rial Sloan-Kettering Cancer Center. Surg Oncol. 1999;8:85–91.

    Article  PubMed  Google Scholar 

  20. Cody HS. Clinical aspects of sentinel node biopsy. Breast Cancer Res. 2001;3:104–8.

    Article  PubMed  Google Scholar 

  21. Shen J, Wallace AM, Bouvet M. The role of sentinel node biopsy for melanoma. Semin Oncol. 2002;29:341–52

    Article  PubMed  Google Scholar 

  22. Krag DM, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg. 1995;130:654–8.

    PubMed  CAS  Google Scholar 

  23. Albertini JJ, Cruse CW, Rapaport D, et al.. Intraoperative radiolympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223:217–24.

    Article  PubMed  CAS  Google Scholar 

  24. Leong SP. The role of sentinel lymph nodes in malignant melanoma. Surg Clin North Am. 2000;80:1741–57.

    Article  PubMed  CAS  Google Scholar 

  25. Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg. 1997;132:666–72.

    PubMed  CAS  Google Scholar 

  26. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253–60.

    PubMed  CAS  Google Scholar 

  27. Gadd MA, Cosimi AB, Yu J, et al.. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134:381–7.

    Article  PubMed  CAS  Google Scholar 

  28. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large singleinstitutional experience with an emphasis on recurrence. Ann Surg. 2001;233:250–8.

    Article  PubMed  CAS  Google Scholar 

  29. Kelley MC, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol. 1998;14:283–90.

    Article  PubMed  CAS  Google Scholar 

  30. Doting MHE, Hoekstra HJ, Plukker JThM, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. EJSO. 2002;28:673–8.

    Article  PubMed  CAS  Google Scholar 

  31. Blaheta HJ, Elwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000; 114:637–42.

    Article  PubMed  CAS  Google Scholar 

  32. Li W, Stall A, Shivers SC, et al. Clinical relevance of molecular staging for melanoma: Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000;231: 795–803.

    Article  PubMed  CAS  Google Scholar 

  33. Goydos JS, Patel KN, Shih WJ, et al. Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg. 2003;196:196–204.

    Article  PubMed  Google Scholar 

  34. Ribuffo, D, Gradilone A, Vonella M, et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol. 2003;10:396–402.

    Article  PubMed  Google Scholar 

  35. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol. 2004:22:3989–96.

    Article  PubMed  Google Scholar 

  36. Coit DG. The “true” sentinel lymph node: in search of an operational definition of a biological phenomenon. Ann Surg Oncol. 2001;8:187–9.

    PubMed  CAS  Google Scholar 

  37. Wagner JD, Gordon MS, Chuang T-Y, et al. Current therapy of cutaneous melanoma. Plast Reconstr Surg. 2000;105:1774–2000.

    Article  PubMed  CAS  Google Scholar 

  38. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–83.

    PubMed  CAS  Google Scholar 

  39. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19: 3635–48.

    PubMed  CAS  Google Scholar 

  40. Thompson JA. The revised American Joint Committee on Cancer staging system for melanoma. Semin Oncol. 2002;29:361–9.

    Article  PubMed  Google Scholar 

  41. Chao C, McMasters KM. Update on the use of sentinel node biopsy in patients with melanoma: who and how. Curr Opin Oncol. 2002;14:217–20.

    Article  PubMed  Google Scholar 

  42. Leiter, U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86;172–8.

    Article  PubMed  Google Scholar 

  43. Eedy DJ. Surgical treatment of melanoma. Br J Dermatol. 2003;149(1):2–12.

    Article  PubMed  CAS  Google Scholar 

  44. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trails. Cancer Treat Rev. 2003;29: 241–52.

    Article  PubMed  CAS  Google Scholar 

  45. Estourgie SH, Nieweg OE, Valdes Olmos RA, Hoefnagel CA, Kroon BBR. Review and evaluation of sentinel node procedures in 250 melanoma patients with median follow up of 6 years. Ann Surg Oncol. 2003;10: 681–8.

    Article  PubMed  Google Scholar 

  46. Statius Muller MG, van Leeuwen PAM, van Diest PJ, et al. Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg. 2002;26:1405–11.

    Article  PubMed  Google Scholar 

  47. Chao C, Wong SL, Ross MI, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am Jour Surg. 2002;184:520–5.

    Article  Google Scholar 

  48. Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. EJSO. 2004;30:686–91.

    Article  PubMed  CAS  Google Scholar 

  49. Stehlin JS Jr, Smith JL, Jr, Jing BS, Sherrin D. Melanomas of the extremities complicated by in-transit metastases. Surg Gynecol Obstet. 1966;122:3–14.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Portuguese Institute of Cancer, Rua Hermíno Monteiro, 3-5°A, 1750-401, Lisbon, Portugal

    Isabel Callejo Peixoto MD & José Menesese Sousa

Authors
  1. Isabel Callejo Peixoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Menesese Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabel Callejo Peixoto MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peixoto, I.C., Sousa, J.M. Clinical and biological aspects of sentinel node biopsy in malignant melanoma — an update. Clin Transl Oncol 7, 145–149 (2005). https://doi.org/10.1007/BF02708751

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02708751

Key words

Search

Navigation